This review assessed the effect of bisphosphonates on skeletal morbidity in people with bone metastases. The authors concluded that, when given for at least 6 months, bisphosphonates decreased skeletal morbidity in metastatic bone disease but did not affect spinal cord compression or survival. The authors did not report full details of the assessment processes and the included studies were diverse.
To assess the effectiveness of bisphosphonates for reducing skeletal morbidity in people with bone metastases.
Searching MEDLINE (1966 to June 2001 , EMBASE (1980 to June 2001 , Cancerlit (1975 to June 2001 , the Science Citation Index Expanded (1981 ( to June 2001 , the Cochrane Library, and the reference lists of articles were searched; the search terms were reported. The authors also handsearched relevant journals and meeting abstracts, and contacted experts in the field and drug companies for unpublished data. There were no language restrictions.
Study selection Study designs of evaluations included in the review
Randomised controlled trials (RCTs) were included.
Specific interventions included in the review
Studies were eligible for inclusion if they compared oral or intravenous bisphosphonate versus another bisphosphonate, placebo or usual care. The intravenous bisphosphonates included pamidronate and zoledronic acid, while the oral bisphosphonates included clodronate and etidronate.
Participants included in the review
Eligible studies included people with confirmed malignant cancer and bone metastases. Haematological malignancies, apart from multiple myeloma, were excluded. The participants were people with breast cancer, multiple myeloma, prostate cancer and various mixed cancer diagnoses.
Outcomes assessed in the review
Eligible studies included at least one skeletal morbidity outcome. The primary outcome measures of the review were time to first skeletal-related event and the reduction in skeletal morbidity assessed by pathological fractures, radiotherapy to bone metastases, spinal cord compression, hypercalcaemia and orthopaedic surgery. The secondary outcomes of interest included the efficacy of bisphosphonates over time, the efficacy of one type over another, the relative effects in different disease groups, the comparison of administration routes, survival and tolerability. Pain relief was not included as an end point because another review has been published on this topic (see Other Publications of Related Interest).
How were decisions on the relevance of primary studies made? Two independent reviewers determined the relevance of studies for inclusion in the review. It was unclear how any disagreements were resolved.
Assessment of study quality
Trials were assessed for allocation concealment (on a scale of A to D) and blinding according to Cochrane guidelines.
The authors did not state how many reviewers performed the validity assessment. All relevant papers were included at
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Data extraction
Two independent reviewers extracted the outcome data as proportions.
Methods of synthesis
How were the studies combined? For studies of at least 6 months' duration, the authors conducted a meta-analysis with a random-effects model. The odds ratio (OR) was used as a summary measure for each outcome. The inverse variance method was used to weight the included studies.
How were differences between studies investigated?
The authors used chi-squared tests to compare groups.
Results of the review
Thirty RCTs fulfilled the inclusion criteria, 18 of which were included in the meta-analyses. These included data from 3 unpublished trials. The number of participants included in each meta-analysis varied (range: 2,543 to 3,894), and the total number of participants overall was not reported.
A meta-analysis of studies (n=18) Eight studies indicated that bisphosphonates statistically significantly increased time to first skeletal-related event and had no effect on survival. A subgroup analysis found that there was most evidence to support intravenous aminobisphosphonates.
The results of other secondary end points were also reported.
